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%LYDOHQW YDFFLQDWLRQ KDV OHG WR D VWDUWOLQJ UHGXFWLRQ LQ YDFFLQH DQG FURVVSURWHFWLYH W\SHV
ZKLFK KDYH DOPRVW GLVDSSHDUHG LQ WKLV SRSXODWLRQ  \HDUV IROORZLQJ YDFFLQDWLRQ:H DOVR















DQG TXDGULYDOHQW YDFFLQHV KDG GLIIHULQJ OHYHOV RI YDFFLQH XSWDNH ZHUH RIWHQ HFRORJLFDO
VWXGLHVFRPSDULQJSUHYDOHQFHLQGLIIHUHQWWLPHIUDPHVDQGZHUHIRFXVHGRQWKRVHYDFFLQDWHG
DWROGHUDJHVDVSDUWRIFDWFKXSFRKRUWV 
On 8 March 2016, we conducted a PubMed search using the same strategy outlined in the 
2015 review - ³SDSLOORPDYLUXV YDFFLQH´ ³SDSLOORPDYLUXV YDFFLQDWLRQ´ ³+39 YDFFLQH´ or ³+39 
YDFFLQDWLRQ´ and ³SURJUDP HYDOXDWLRQ´ ³SRSXODWLRQ VXUYHLOODQFH´ ³VHQWLQHO VXUYHLOODQFH´ 
³LQFLGHQFH´ or ³SUHYDOHQFH´, with 151 articles published in the intervening period (1 Feb 2014-
8 March 2016), and found a further 6 studies, including our own work, reporting population-
based HPV prevalence in vaccinated populations from England, Scotland, Sweden, Australia 
and USA (2 studies) with all bar the UK studies evaluating the impact of the quadrivalent 
vaccine. The populations studied were generally vaccinated during catch-up campaigns and 
were attending cervical screening at age 25 or above, or were vaccinated at an earlier age 
and observed as part of screening high risk populations or through national surveys using self-
collected samples. For the majority of studies, individual vaccination status was not known, 
rather changes in HPV prevalence pre- and post-vaccination were examined. No studies have 
currently presented population-based evidence for those vaccinated at age 12/13 where 
vaccine status is known.  With the exception of our own work, no statistically significant 
evidence of vaccine effectiveness for the grouping of the cross-protective types was found in 











7KHVH UHGXFWLRQV LQ WKH PRVW FDUFLQRJHQLF W\SHV RI +39 ZKLFK DUH LPSOLFDWHG LQ  RI
FHUYLFDO FDQFHUV LQ 6FRWODQG KDYH FOHDU LPSOLFDWLRQV IRU FHUYLFDO VFUHHQLQJ LQ WKDW WKH
SUHGLFWLYHYDOXHRIF\WRORJ\DQG+39EDVHGVFUHHQLQJVWUDWHJLHVZLOOUHGXFH'HILQLQJRSWLPDO
VFUHHQLQJ LQWHUYDOVDJH UDQJH WHVWDQG WULDJHVWUDWHJLHV IRUYDFFLQDWHGZRPHQVKRXOGEH
SULRULWLHVIRUUHVHDUFK2XUILQGLQJVVKRXOGLQIRUPWKHHYDOXDWLRQRIVFUHHQLQJSURJUDPPHVLQ
YDFFLQDWHGSRSXODWLRQVZLWKKLJKOHYHOVRIXSWDNH7KHUHPD\EHDWLPHZKHQFXUUHQWF\WRORJ\
RU+39EDVHGFHUYLFDOVFUHHQLQJSURJUDPPHVDUHQR ORQJHUFRVWHIIHFWLYH ,QDGGLWLRQ WKH
OHYHOVRIYDFFLQHHIIHFWLYHQHVVREVHUYHGLQSDUWLFXODUIRUWKHFURVVSURWHFWLYHW\SHVPD\KDYH
LPSOLFDWLRQVIRUWKHFRPSDUDWLYHFRVWHIIHFWLYHQHVVDVVHVVPHQWRIWKHELYDOHQWTXDGULYDOHQW
DQG QRQDYDOHQW +39 YDFFLQHV DQG RXU ILQGLQJV VKRXOG EH LQFRUSRUDWHG LQ WKH EDVHOLQH







Human papillomavirus (HPV) types 16 and 18 are responsible for 70-80% of cervical cancers 
in the UK1. HPV vaccination prevents infection with HPV 16 and 182-4 and is associated with 
a reduction in all grades of histological and cytological abnormalities according to data from 
population-based immunisation programmes5, 6.  The bivalent vaccine also provides 
immunological cross-protection against HPV 31, 33 and 45, high-risk oncogenic HPV types 
phylogenetically related to HPV 16 and 18, although the duration and scale of long-term cross-
protective immunity has been vigorously debated3, 7-9. The persistence of the cross-reactive 
antibody titres against HPV 31 and 45 after bivalent HPV vaccination has been demonstrated 
up to 9.4 years after the initial dose in the clinical trial setting10. These data are particularly 
relevant for Scotland since at least 90% of invasive cervical cancers are attributable to HPV 
16, 18, 31, 33 and 4511.  
 
To date, HPV vaccine impact data2-4, 7, 12 through national vaccination programmes are largely 
obtained from females immunised as part of ³catch-XS´ cohorts which, in Scotland, included 
girls up to age 18.  While data derived from catch-up populations have been encouraging, they 
are likely to underestimate the effect as some females will have been exposed to HPV before 
vaccination. Cervical screening programmes, which constitute a critical and enriched resource 
for both monitoring HPV prevalence and outcomes, mostly screen from age 25 or older. 
Assessment of vaccine impact, prior to screening, has been possible either ecologically by 
conducting HPV testing in higher risk populations attending chlamydia screening13-15 or via 
national surveys16 reliant on self-reported vaccine status and self-collected samples.  There 
has thus far been limited opportunity to observe changes in prevalence in women routinely 
vaccinatedat age 12/13.  
 
Until June 2016, cervical screening started aged 20 in Scotland. Therefore, using the ability 
to link individual screening and vaccination records, we can now report on effectiveness of the 
bivalent vaccine on both low- and high-risk HPV infections in 12/13-year old girls, of whom 
92.4% were fully vaccinated in 2008/917. Timely production and analyses of these data have 
significant implications for service planning and cost-effectiveness modelling to inform future 




,Q6HSWHPEHU6FRWODQGEHJDQschool-based routine HPV vaccination, targeted at 12- 
13-year-old girls. Between 1 September 2008 and 31 August 2011, a 3-year catch-up 
programme for older girls (aged 13±18 years, born between 01/09/90 to 31/08/95) was also 
delivered, both at school and, for school leavers, at Health Board-run vaccination clinics or 
general practices. The 3-year catch-up programme attained a high uptake (87%) for all three 
doses among those vaccinated in school but a lower uptake (32%) was achieved in school 
leavers18.  Bivalent vaccination was delivered until September 2012 when a switch was made 
to quadrivalent vaccination.  All females in our study period were eligible for the bivalent 
vaccination. 
 
Since 2009, Health Protection Scotland (HPS) has co-ordinated a national HPV immunisation 
surveillance programme19 to assess the impact of HPV vaccine on viral and disease 
outcomes3-5, 20, 21.  This includes the assessment of type-specific HPV prevalence in females 
attending for their first cervical screen. This has been achieved by yearly (cross-sectional) 
collection and HPV genotyping of approximately 1000 residual liquid-based cytology (LBC) 
samples from women aged 20±21 from the years 2009 to 2015. Each sampling year covers 
at least two birth year cohorts for example, in 2009, individuals from 1988 and 1989 birth 
cohorts were sampled and in 2015, the collection primarily covered individuals from the 1994 
and 1995 cohorts. Vaccinated girls mainly entered the cervical screening programme from 
2011 and the inclusion of samples from 2009 and 2010 provides a relevant comparator group 
of those not offered vaccination through the National Health Service (NHS) immunisation 
programme. 
 
Residual LBC samples from cervical screening were collected from all 8 NHS cytopathology 
laboratories in Scotland. Each laboratory collected residual samples over a 1-2 month period, 
staggered throughout the year, to balance the workload. The target number from each 
laboratory was dictated by the size of the population served by the laboratory, ensuring a 
geographically representative sample. Each laboratory collected sequential residual LBC 
samples fromZRPHQDJHGDWWHQGLQJLQWKRVHPRQWKVXQWLOWKH\KDGPHWWKHLUWDUJHW
$SDUWIURPDJHQRRWKHULQIRUPDWLRQZDVNQRZQDERXWWKHZRPHQDWWKHSRLQWRIFROOHFWLRQ
Samples were given a laboratory identification number and underwent HPV genotyping at the 
Scottish HPV Reference Laboratory (SHPVRL). 2YHUVDPSOLQJ ZDV FRQGXFWHG LQ  WR
HVWDEOLVKDEDVHOLQH The 2015 collection was extended into 2016 to maximise capture of those 




QXPEHU Cytopathology laboratories sent the ODERUDWRU\ LGHQWLILFDWLRQ QXPEHU DQG WKH &+,





'HSULYDWLRQ 6,0' ± WKH 6FRWWLVK *RYHUQPHQWV RIILFLDO WRRO WR LGHQWLI\ DUHDV RI PXOWLSOH
GHSULYDWLRQEDVHGRQFRPELQLQJLQIRUPDWLRQRQVHYHQGRPDLQVFRYHULQJHPSOR\PHQWLQFRPH
FULPH KRXVLQJ KHDOWK HGXFDWLRQ DQG DFFHVV (DFK LQGLYLGXDO LV FDWHJRULVHG LQWR 6,0'
TXLQWLOHV 6,0'    PRVW GHSULYHG DQG 6,0'    OHDVW GHSULYHG$Q DQRQ\PRXV SDWLHQW
LGHQWLILHU ZDV WKHQ DVVLJQHG WR DOO UHFRUGV WKH&+, DQG SRVWFRGH ZHUH UHPRYHG DQG WKH
UHVXOWLQJ GDWD VHQW WR +36 +39 WHVW UHVXOWV DQG ODERUDWRU\ LGHQWLILFDWLRQ QXPEHU ZHUH



































DQ\ W\SH GHWHFWHG E\ WKH JHQRW\SLQJ +39 DVVD\ ,Q DGGLWLRQ +39   DQG  ZHUH





1DWLRQDO VXUYHLOODQFH ZDV DSSURYHG WKURXJK WKH 1+6 1DWLRQDO &OLQLFDO *RYHUQDQFH













7KH UHPDLQLQJ  VDPSOHV ZHUH VXFFHVVIXOO\ +39 JHQRW\SHG DQG IRUPHG WKH VWXG\
SRSXODWLRQ6XSSOHPHQWDU\7DEOHGHVFULEHVWKHEUHDNGRZQE\\HDU,QWKHFROOHFWLRQ
\HDU IHPDOHVDWWHQGLQJ IRU ILUVWVPHDUERUQ LQDQGZHUHQRWHOLJLEOH IRU URXWLQH




























EXW FRPSDUDEOH WR WKDW IRU WKH YDFFLQH W\SHV LQ JLUOV YDFFLQDWHG DW DJH  6LJQLILFDQW
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YDFFLQHHIIHFWLYHQHVVZDVREVHUYHGIRU+39DQGLQGLYLGXDOO\LQWKRVHYDFFLQDWHGDW
DJH  ZLWK KLJKHVW OHYHOV REVHUYHG IRU +39  DQG ORZHVW IRU +39  +39 
9(   &,  +39  9(   &,  +39 
9( &,)RUIXOOGHWDLOVVHH6XSSOHPHQWDU\7DEOH 
)LJXUH&LOOXVWUDWHVWKDWDOWKRXJKWKHUHZHUH\HDUO\IOXFWXDWLRQVLQWKHSUHYDOHQFHRI+5+39











RI DGHFOLQLQJ WUHQGZLWK FRKRUW \HDU OLQHDUS6XSSOHPHQWDU\7DEOHZLWK OHYHOV









WKH   DQG  ELUWK FRKRUWV ([DPLQLQJ WKH FKDQJH LQ SUHYDOHQFH LQ WKH





DJDLQVWFURVVSURWHFWLYH+39 W\SHV6HQVLWLYLW\DQDO\VLV IRFXVLQJRQ WKHXQYDFFLQDWHGZKR




Population-based data from the Scottish HPV immunisation programme clearly demonstrates 
that WKH bivalent vaccine is associated with a significant reduction in the prevalence of HPV 
16/18 and each of the cross protective types 31, 33 and 45 in those attending for routine 
cervical screening. The magnitude of this effect increases with successive birth cohorts. 
Moreover, we can demonstrate that cross-protection remains high at age 20 for girls 
vaccinated at age 12-13, differing from an earlier PHWDDQDO\VLVRIFOLQLFDO WULDOGDWD which 
postulated that WKHUHPD\EHZDQLQJRIFURVVSURWHFWLRQRYHUWLPH 
The implications of these findings are significant. According to global meta-analyses HPV 
16,18,31,33 and 45 are implicated in 84% of invasive cervical cancers25 and in Scotland these 
5 HPV types account for 90% of cancers11.  For all 5 types, vaccine effectiveness in those 
vaccinated at age 12-13 exceeded 79%. This differs from recent meta-analysis7 which found 
evidence for HPV 31 cross-protection but little evidence for reductions of HPV 33 or 45. This 
meta-analysis was potentially influenced by inclusion of results for both the bivalent and 
quadrivalent vaccines as the latter has previously been shown to have lower levels of cross-
protection8, by stratification by vaccine availability period (pre and post) rather than known 
vaccination status, and by the inclusion of studies with low population vaccine uptake. Our 
results suggest that the high levels cross-protection associated with the bivalent vaccine may 
have been underestimated in the baseline assumptions of cost-effectiveness models. 
Recalibration of such models may impact future vaccine choice with a recent review26 
highlighting that ³the 9-valent was not cost-effective (vs 2-valent), under assumptions of 
maximum cross-protection for the 2-valent YDFFLQH´  
We have demonstrated that partial vaccination conveys protection against HPV16/18 albeit at 
a lower level (2 dose VE=39%, 1 dose VE=27.6%). However, it is important to emphasise that 
the majority of those receiving partial vaccination were vaccinated as part of the catch-up 
cohorts at age 16 and over. Comparable 3 dose VE was 75.9% in those vaccinated at age 16, 
58.1% at age 17 and 28.9% at age 18. It should also be noted that the 2 dose schedule was 
generally delivered as planned within a 3 dose regime i.e. at 0 and 1 month rather than at the 
current 2 dose recommended scheduling of 0 and 6 months, where higher VE would be 
expected. Partial vaccination in older women shown to be HPV-negative, as suggested by the 
HPV Faster protocol27 for accelerated reduction of cervical cancer incidence, may also have 
a higher VE.  Given the age range of women considered for HPV Faster, they are likely to be 
largely unaffected by genital warts and there may be merit in offering bivalent vaccine to these 
women.  
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Encouragingly, there was no significant increase in non-16/18/31/33/45 HR-HPV types even 
though 16/18 prevalence has reduced by 6-fold (28.9% to 4.8%). There is therefore no 
evidence of ³type UHSODFHPHQW´ at least in the shorter term. However, for this to be addressed 
robustly further longitudinal studies which relate infecting HPV type to the future risk of disease 
in immunised populations are required and ongoing in the Scottish population.   
Retesting the 59 samples in the 1995 cohort that were positive for 16/18 according to the 
epidemiologically orientated assay with a clinically validated assay (with a cut off set for the 
detection of CIN2+)24, showed that only 7 (4 vaccinated) were HPV 16 positive and none were 
HPV 18 positive. This suggest that the majority of HPV 16 infection in routinely immunised 
women may be at thresholds that are clinically irrelevant. Analytically sensitive assays are 
also more likely to detect HPV associated with recent acquisition rather than actual intra-
cellular infection which has the capacity to persist. Follow up studies to determine the clinical 
significance of residual infection in vaccinated women are underway to examine this more 
specifically. 
We previously showed preliminary evidence, based on small numbers, of herd protection in 
the unvaccinated population for the vaccine types4. Scotland has benefitted from high uptake 
rates of vaccine of around 90% in the routine cohort since initiation of the programme. The 
growing evidence of herd protection extending to the cross-protective types serves as a 
positive, reinforcing message for future and existing programmes in their drive to achieve and 
maintain high uptake levels.  
Reduced HPV 16/18/31/33/45 infection will naturally have implications for screening, as 
current modalities have been calibrated to pre-vaccination era levels of disease. The positive 
predictive value (PPV) of a screening test will reduce as the prevalence of target disease 
reduces28. Data derived from the population vaccinated as part of catch-up in Scotland has 
already shown a significant reduction in the PPV of cytology for CIN2+ in immunised women21. 
While it is argued that HPV primary screening using objective molecular assays may mitigate 
the issues of cytology screening, it is subject to the same influences as cytology and is not a 
panacea. The randomised controlled trials which provided evidence for its introduction have 
been based solely on unvaccinated women29. 
Compared to other high-risk types, HPV 16/18 have been shown to confer a significantly 
higher risk of disease30, particularly HPV 16 and particularly when CIN3 or worse is used as 
an outcome. Consequently, residual HR-HPV infection in immunised women will be clinically 
less significant. In line with this, preliminary data on the clinical performance of HPV testing 
for primary screening in Scotland indicated that the positive predictive value for CIN2+ was 
significantly lower in vaccinated women compared to unvaccinated women31. Therefore, 
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robust ³WULDJH´ for primary HPV testing becomes increasingly relevant for immunised 
populations. The choice of optimal triage is a fertile area of research and extended genotyping, 
methylation and cytology with adjunctive biomarker staining represent some of the many 
options under consideration32. Furthermore, an ecological study which assessed national 
colposcopy data in Scotland before and after the introduction of vaccination, showed that WKH
PPVRIFROSRVFRS\IRU&,1GHFUHDVHGIURPLQWRLQclose to the 
UK key performance indicator threshold of  65%33 . 
7KHUH DUH limitations to this study. The sample collection and testing strategy necessarily 
involved only those women who attended screening who represent only 50% of their age 
group34. In our study vaccine XSWDNHILJXUHVDUHWKHVDPHDVLQWKHJHQHUDOSRSXODWLRQ7KHUH
LV WKHUHIRUHQRVXEVWDQWLDOELDV LQZKRFRPHVWRVFUHHQLQJZLWK UHVSHFW WRYDFFLQHUHFHLSW 
This coupled with the equity of vaccine uptake18 in the routinely vaccinated cohorts in 
Scotland, and the similarity in HPV positivity levels in 2009/10 between screening attenders 
and non-attenders20, should mitigate any differential vaccine effect in non-attenders who were 
vaccinated at younger ages. In those vaccinated as part of the catch-up cohorts who had lower 
overall uptake, our previous work18 has shown lowest uptake of vaccination in the most 
deprived,  a group disproportionately affected by cervical malignancy. Our results show that 
there remains a deprivation effect in HPV positivity and, whilst this effect may be driven by 
inequitable vaccine uptake in the catch-up cohorts, perhaps in addition to differences in sexual 
behaviour and smoking status (which we cannot ascertain in our study), they reinforce the 
need for appropriate delivery and uptake of cervical screening. 
 
:LWKWKHFKDQJHWRTXDGULYDOHQWYDFFLQDWLRQLQIXWXUHZRUNWRH[DPLQHYDFFLQHLPSDFW
ERWK LQ WHUPVRIKHUGSURWHFWLRQDQGGLUHFWSURWHFWLRQZLOOEHFRQIRXQGHGE\ WKH LQHYLWDEOH
VH[XDOPL[LQJRIWKHWZRYDFFLQDWLRQFRKRUWV,QWKLVVWXG\KRZHYHUWKH\HDUJDSEHWZHHQ
WKH\HDUROGVYDFFLQDWHGLQDQGWKHILUVWTXDGULYDOHQWFRKRUWLQFRXSOHG




To conclude, HPV 16, 18, 31, 33, and 45 have reduced substantially following a population-
based vaccination programme which has achieved high uptake of bivalent vaccine. Levels of 
cross-protective immunity endure for at least 7 years and further follow-up will provide 
important information as to their ultimate longevity. The massive reductions in the most 
carcinogenic types of HPV have clear implications for cervical screening and disease 
management and there may be a time when the current cervical screening programme is no 
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longer cost-effective. Primary screening with HPV testing already allows extended screening 
intervals compare to cytology, and immunisation will permit even longer intervals and possibly 
a rise in the age at which screening starts in developed countries35. The levels of sustained 
cross protection observed with bivalent vaccine may also have implications for future vaccine 
choice, which needs to be matched to the prevalence of HPV types in the target population. 
Indeed, if the cross protection observed translates to fewer HPV related cancer cases in a 
population, then there are likely to be implications for the cost effectiveness of the bivalent 
vaccine relative to alternative HPV vaccines.  It is therefore imperative that data such as those 
described above are incorporated into models which can inform optimal strategies for future 
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DQG .DWH &XVFKLHUL .HYLQ * 3ROORFN PDQDJHG WKH QDWLRQDO VXUYHLOODQFH V\VWHP ZLWK WKH

























RI WKH +39 YDFFLQDWLRQ SURJUDPPH RQ FHUYLFDO DEQRUPDOLWLHV LQ 9LFWRULD $XVWUDOLD DQ
HFRORJLFDOVWXG\/DQFHW 










LPPXQRJHQLFLW\ DJDLQVW+39DQG+39QRQYDFFLQHRQFRJHQLF W\SHVXS WR \HDUV
IROORZXS>$EVWUDFW+39@3URFHHGLQJVRIWKH,QWHUQDWLRQDO3DSLOORPDYLUXV6RFLHW\
WK,QWHUQDWLRQDO3DSLOORPDYLUXV&RQIHUHQFH/LVERQ3RUWXJDO6HS 
 0HVKHU'&XVFKLHUL.+LEELWWV6 -DPLVRQ-6DUJHQW$3ROORFN.* HW DO7\SH











SDSLOORPDYLUXV DIWHU LQLWLDWLRQ RI YDFFLQDWLRQ WKH KLJKWKURXJKSXW +39 PRQLWRULQJ VWXG\
&DQFHU(SLGHPLRO%LRPDUNHUV3UHY 
 &KRZ(3'DQLHOHZVNL-$)HKOHU*7DEUL]L61/DZ0*%UDGVKDZ&6HWDO+XPDQ
SDSLOORPDYLUXV LQ \RXQJ ZRPHQ ZLWK &KODP\GLD WUDFKRPDWLV LQIHFWLRQ  \HDUV DIWHU WKH
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$XVWUDOLDQ KXPDQ SDSLOORPDYLUXV YDFFLQDWLRQ SURJUDPPH D FURVVVHFWLRQDO VWXG\ /DQFHW
,QIHFW'LV 
 0DUNRZLW]/(/LX*+DULUL66WHLQDX0'XQQH()8QJHU(53UHYDOHQFHRI+39
$IWHU ,QWURGXFWLRQ RI WKH 9DFFLQDWLRQ 3URJUDP LQ WKH 8QLWHG 6WDWHV 3HGLDWULFV
H 
 7UHQGVLQ+39LPPXQLVDWLRQXSWDNHUDWHVIRU6URXWLQHFRKRUWE\WKHHQGRIWKHVFKRRO




DQG HTXLWDEOH FRYHUDJH RI DGROHVFHQW +39 YDFFLQH LQ 6FRWODQG - (SLGHPLRO &RPPXQLW\
+HDOWK 
 1DWLRQDO6XUYHLOODQFH6\VWHPIRU+XPDQ3DSLOORPDYLUXV,QIHFWLRQDQG5HODWHG'LVHDVH
LQ 6FRWODQG +HDOWK 3URWHFWLRQ 6FRWODQG  >$YDLODEOH IURP
KWWSZZZKSVVFRWQKVXNUHVRXUFHGRFXPHQWDVS["UHVRXUFHLG  
 .DYDQDJK.6LQND.&XVFKLHUL./RYH-3RWWV$3ROORFN.*HWDO(VWLPDWLRQRI
+39 SUHYDOHQFH LQ \RXQJ ZRPHQ LQ 6FRWODQG PRQLWRULQJ RI IXWXUH YDFFLQH LPSDFW %0&
,QIHFW'LV 
 3DOPHU7-0F)DGGHQ03ROORFN.*.DYDQDJK.&XVFKLHUL.&UXLFNVKDQN0HW
DO +39 LPPXQLVDWLRQ DQG FHUYLFDO VFUHHQLQJFRQILUPDWLRQ RI FKDQJHG SHUIRUPDQFH RI
F\WRORJ\ DV D VFUHHQLQJ WHVW LQ LPPXQLVHGZRPHQ D UHWURVSHFWLYHSRSXODWLRQEDVHGFRKRUW
VWXG\%U-&DQFHU 














EURDGHQLQJ WKH VFRSH IRU SUHYHQWLRQ RI +39UHODWHG FDQFHU 1DW 5HY &OLQ 2QFRO
 


























Table 1:  Positivity for HPV 16/18 and HPV31/33/45 by birth cohort, number of vaccine doses, SIMD quintile, collection year and age 
at vaccination. *p-value evaluated as a test of linear trend by including the variable as an ordered factor in a logistic regression model 







Positive (95% CI) 
Unadjusted OR 




Positive (95% CI) 
Unadjusted OR 
(95% CI) p-value* 
Birth cohort 1988 838 251 30.0 (26.9,33.1) 1.00 (-,-) <0.0001 119 14.2 (12.0,16.7) 1.00 (-,-) <0.0001 
  1989 1180 345 29.2 (26.7,31.9) 0.97 (0.80,1.17)  140 11.9 (10.1,13.8) 0.81 (0.63,1.06)   
  1990 1255 367 29.2 (26.8,31.8) 0.97 (0.80,1.17)   162 12.9 (11.2,14.9) 0.90 (0.70,1.16)   
  1991 940 187 19.9 (17.5,22.6) 0.58 (0.47,0.72)   87 9.3 (7.6,11.3) 0.62 (0.46,0.83)   
  1992 1324 186 14.0 (12.3,16.0) 0.38 (0.31,0.47)   98 7.4 (6.1,8.9) 0.48 (0.36,0.64)   
  1993 1022 116 11.4 (9.5,13.4) 0.30 (0.23,0.38)   73 7.1 (5.7,8.9) 0.47 (0.34,0.63)   
  1994 708 51 7.2 (5.5,9.3) 0.18 (0.13,0.25)   30 4.2 (3.0,6.0) 0.27 (0.17,0.40)   
  1995 1317 59 4.5 (3.5,5.7) 0.11 (0.08,0.15)   34 2.6 (1.9,3.6) 0.16 (0.11,0.23)   
Number doses 0 4008 1116 27.8 (26.5,29.3) 1.00 (-,-) <0.0001 504 12.6 (11.6,13.6) 1.00 (-,-) <0.0001 
  1 223 50 22.4 (17.4,28.3) 0.75 (0.54,1.03)  30 13.5 (9.6,18.6) 1.08 (0.71,1.58)   
 2 391 76 19.4 (15.8,23.6) 0.63 (0.48,0.81)   32 8.2 (5.9,11.3) 0.62 (0.42,0.89)   
  3 3962 320 8.1 (7.3,9.0) 0.23 (0.20,0.26)   177 4.5 (3.9,5.2) 0.33 (0.27,0.39)   
SIMD quintile 1: Most deprived 1976 412 20.9 (19.1,22.7) 1.00 (-,-) <0.0001 195 9.9 (8.6,11.3) 1.00 (-,-) <0.0001 
  2 1739 324 18.6 (16.9,20.5) 0.87 (0.74,1.02)  179 10.3 (9.0,11.8) 1.05 (0.85,1.30)   
  3 1630 291 17.9 (16.1,19.8) 0.83 (0.70,0.97)   146 9.0 (7.7,10.4) 0.90 (0.72,1.13)   
  4 1519 282 18.6 (16.7,20.6) 0.87 (0.73,1.02)   110 7.2 (6.0,8.7) 0.71 (0.56,0.91)   
  5: Least deprived 1720 253 14.7 (13.1,16.5) 0.66 (0.55,0.78)   113 6.6 (5.5,7.8) 0.64 (0.50,0.82)   
Collection year 9 1656 478 28.9 (26.7,31.1) 1.00 (-,-) <0.0001 215 13.0 (11.4,14.7) 1.00 (-,-) <0.0001 
  10 1101 344 31.2 (28.6,34.0) 1.12 (0.95,1.32)   148 13.4 (11.6,15.6) 1.04 (0.83,1.30)   
  11 1074 251 23.4 (20.9,26.0) 0.75 (0.63,0.90)   110 10.2 (8.6,12.2) 0.77 (0.60,0.97)   
  12 1051 179 17.0 (14.9,19.4) 0.51 (0.42,0.61)   90 8.6 (7.0,10.4) 0.63 (0.48,0.81)   
  13 1073 116 10.8 (9.1,12.8) 0.30 (0.24,0.37)   70 6.5 (5.2,8.2) 0.47 (0.35,0.62)   
  14 1019 117 11.5 (9.7,13.6) 0.32 (0.26,0.40)   61 6.0 (4.7,7.6) 0.43 (0.32,0.57)   
  15 1610 77 4.8 (3.8,5.9) 0.12 (0.10,0.16)   49 3.0 (2.3,4.0) 0.21 (0.15,0.29)   
Age at vaccination 12-13 976 39 4.0 (2.9,5.4) 1.00 (-,-) <0.0001 20 2.0 (1.3,3.1) 1.00 (-,-) <0.0001 
  14 283 15 5.3 (3.2,8.6) 1.35 (0.71,2.43)   9 3.2 (1.7,5.9) 1.57 (0.67,3.39)   
  15 986 74 7.5 (6.0,9.3) 1.95 (1.32,2.93)   45 4.6 (3.4,6.1) 2.29 (1.36,3.98)   
  16 1319 123 9.3 (7.9,11.0) 2.47 (1.72,3.62)   85 6.4 (5.2,7.9) 3.29 (2.05,5.54)   
  17 571 96 16.8 (14.0,20.1) 4.86 (3.32,7.23)   39 6.8 (5.0,9.2) 3.50 (2.05,6.18)   
  18 359 70 19.5 (15.7,23.9) 5.82 (3.87,8.87)   30 8.4 (5.9,11.7) 4.36 (2.46,7.89)   
  Over 18 82 29 35.4 (25.9,46.2) 13.15 (7.53,22.90)   11 13.4 (7.7,22.4) 7.41 (3.31,15.81)   




 HPV 16/18 HPV31/33/45 Other HR HPV Any HPV 
   Adjusted OR (95% CI) Adjusted OR (95% CI) Adjusted OR (95% CI) Adjusted OR (95% CI) 
Birth cohort  1988  1.00 (-,-) 1.00 (-,-) 1.00 (-,-) 1.00 (-,-) 
 1989  0.96 (0.79,1.17) 0.81 (0.62,1.06) 1.19 (0.98,1.44) 1.11 (0.93,1.33) 
  1990  1.06 (0.88,1.29) 0.99 (0.77,1.28) 1.38 (1.14,1.68) 1.11 (0.93,1.33) 
  1991  0.92 (0.73,1.18) 0.92 (0.67,1.27) 1.34 (1.07,1.68) 1.29 (1.04,1.59) 
  1992  0.70 (0.54,0.89) 0.81 (0.58,1.12) 1.40 (1.13,1.74) 1.17 (0.95,1.43) 
  1993  0.54 (0.41,0.70) 0.77 (0.55,1.09) 1.35 (1.08,1.69) 1.10 (0.89,1.36) 
  1994  0.37 (0.26,0.51) 0.49 (0.31,0.77) 1.42 (1.11,1.81) 1.17 (0.93,1.48) 
  1995  0.24 (0.17,0.33) 0.31 (0.20,0.48) 1.20 (0.96,1.50) 0.86 (0.69,1.06) 
Number doses Unvaccinated 
 
1.00 (-,-) 1.00 (-,-) 1.00 (-,-) 1.00 (-,-) 
  1 dose 
 
0.89 (0.63,1.25) 1.10 (0.71,1.65) 1.06 (0.79,1.42) 1.10 (0.82,1.47) 
 2 dose 
 
0.75 (0.57,0.99) 0.64 (0.42,0.93) 1.11 (0.88,1.40) 1.06 (0.84,1.33) 
  3 dose  
 





1.00 (-,-) 1.00 (-,-) 1.00 (-,-) 1.00 (-,-) 
  2 
 
0.85 (0.72,1.01) 1.05 (0.85,1.31) 1.03 (0.90,1.18) 0.95 (0.84,1.09) 
  3 
 
0.83 (0.70,0.99) 0.92 (0.73,1.15) 0.98 (0.85,1.12) 0.87 (0.76,1.00) 
  4 
 





0.72 (0.60,0.86) 0.70 (0.55,0.89) 0.86 (0.75,0.99) 0.77 (0.68,0.88) 
  












$GMXVWHG  VE 
(95% CI) 




$GMXVWHG  VE 
(95% CI) 
12-13 3 doses 971 39 89.1 (85.1, 92.3) 20 85.1 (77.3, 90.9) 296 7.8 (-7.3, 20.9) 456 38.1 (28.7, 46.3) 
 21 
14 3 doses 269 12 87.7 (78.9, 93.5) 6 83.6 (66.2, 93.6) 86 0.2 (-29.6, 23.8) 134 29.6 (9.8, 45.1) 
15 3 doses 880 56 82.3 (76.8, 86.7) 37 69.2 (57.2, 78.5) 293 -4.8 (-22.3, 10.3) 465 21.7 (9.3, 32.4) 
16 3 doses 1156 97 75.9 (70.2, 80.8) 66 56.8 (44, 67.1) 412 -17.1 (-34.3, -2) 640 12.5 (0.1, 23.4) 
17 3 doses 422 59 58.1 (44.8, 68.8) 24 57.9 (37.2, 73.1) 141 -4.9 (-29.5, 15.4) 234 13.8 (-5.6, 29.6) 
18 and over 3 doses 264 57 28.9 (4.5, 47.8) 24 29.5 (-6.2, 55.3) 75 16.9 (-9.0, 37.2) 144 16.5 (-7.4, 35.0) 
All agesÁ 2 doses 391 76 39 (21.3, 53.3) 32 40.3 (14.5, 59.7) 146 -23.1 (-52.5, 1) 244 -12.5 (-39.7,  9.1) 
All ages§ 1 dose 223 50 27.6 (0.7, 48) 30 -3.6 (-51.7, 31.6) 81 -17.3 (-54.9, 11.8) 141 -15.9 (-53.8, 12.2) 
All ages Unvaccinated 4008 1116 - 504 - 1297 - 2366 - 
Table 2: Adjusted odds of HPV positivity for each HPV grouping by birth cohort, number of doses received and SIMD quintile. 
*HR HPV not 16/18/31/33/45   
 Vaccine Effectiveness (VE) adjusted for SIMD quintile.  All VE calculated at baseline level of SIMD (SIMD quintile 1: most deprived).  VE is 
calculated relative to those unvaccinated across all study years. 
Á2 doses age split:  5 age 12-13, 8 age 14, 71 age 15, 102 age 16, 95 age 17, 87 age 18, 23 over 18.  On average (median) those in receipt of 2 
doses were administered at 49 days apart. 
§1 dose age split:  0 age 12-13, 6 age 14, 35 age 15, 61 age 16, 54 age 17, 43 age 18, 24 over 18 
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Table 3:  HPV positivity in those unvaccinated in each birth cohort *HR HPV not 
















HPV 16/18 1988 836 250 29.9 (26.9,33.1) 1.00 (-,-) 1.00 (-,-) 
  1989 1176 342 29.1 (26.6,31.7) 0.96 (0.79,1.17) 0.96 (0.79,1.16) 
  1990 1014 308 30.4 (27.6,33.3) 1.02 (0.84,1.25) 1.01 (0.83,1.24) 
  1991 282 85 30.1 (25.1,35.7) 1.01 (0.75,1.36) 1.00 (0.74,1.34) 
  1992 252 64 25.4 (20.4,31.1) 0.80 (0.58,1.10) 0.79 (0.57,1.09) 
  1993 197 44 22.3 (17.1,28.6) 0.67 (0.47,0.97) 0.66 (0.46,0.95) 
  1994 99 15 15.2 (9.4,23.5) 0.42 (0.24,0.74) 0.42 (0.24,0.74) 
  1995 152 8 5.3 (2.7,10) 0.13 (0.06,0.27) 0.13 (0.06,0.28) 
HPV31/33/45 1988 836 118 14.1 (11.9,16.6) 1.00 (-,-) 1.00 (-,-) 
  1989 1176 139 11.8 (10.1,13.8) 0.82 (0.63,1.06) 0.81 (0.62,1.06) 
  1990 1014 146 14.4 (12.4,16.7) 1.02 (0.79,1.33) 1.04 (0.80,1.35) 
  1991 282 36 12.8 (9.4,17.2) 0.89 (0.60,1.33) 0.87 (0.58,1.30) 
  1992 252 25 9.9 (6.8,14.2) 0.67 (0.42,1.06) 0.67 (0.42,1.06) 
  1993 197 22 11.2 (7.5,16.3) 0.77 (0.47,1.24) 0.75 (0.46,1.22) 
  1994 99 8 8.1 (4.2,15.1) 0.54 (0.25,1.13) 0.53 (0.25,1.12) 
  1995 152 10 6.6 (3.6,11.7) 0.43 (0.22,0.84) 0.45 (0.23,0.89) 
Other HR* 1988 836 234 28 (25.1,31.1) 1.00 (-,-) 1.00 (-,-) 
  1989 1176 370 31.5 (28.9,34.2) 1.18 (0.97,1.44) 1.18 (0.97,1.43) 
  1990 1014 365 36 (33.1,39) 1.45 (1.19,1.76) 1.45 (1.19,1.77) 
  1991 282 97 34.4 (29.1,40.1) 1.35 (1.01,1.80) 1.34 (1.01,1.79) 
  1992 252 90 35.7 (30.1,41.8) 1.43 (1.06,1.93) 1.45 (1.07,1.95) 
  1993 197 59 29.9 (24,36.7) 1.10 (0.78,1.55) 1.11 (0.79,1.55) 
  1994 99 32 32.3 (23.9,42) 1.23 (0.79,1.92) 1.23 (0.78,1.92) 
  1995 152 50 32.9 (25.9,40.7) 1.26 (0.87,1.83) 1.28 (0.88,1.86) 
Any HPV 1988 836 475 56.8 (53.4,60.1) 1.00 (-,-) 1.00 (-,-) 
  1989 1176 699 59.4 (56.6,62.2) 1.11 (0.93,1.33) 1.11 (0.93,1.33) 
  1990 1014 608 60 (56.9,62.9) 1.14 (0.95,1.37) 1.14 (0.95,1.38) 
  1991 282 188 66.7 (61,71.9) 1.52 (1.15,2.02) 1.50 (1.13,1.99) 
  1992 252 158 62.7 (56.6,68.4) 1.28 (0.96,1.71) 1.29 (0.96,1.72) 
  1993 197 110 55.8 (48.9,62.6) 0.96 (0.70,1.31) 0.95 (0.69,1.30) 
  1994 99 53 53.5 (43.8,63) 0.88 (0.58,1.33) 0.88 (0.58,1.33) 
  1995 152 75 49.3 (41.5,57.2) 0.74 (0.52,1.05) 0.77 (0.54,1.09) 
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Figure 1: Impact of vaccination on HPV prevalence by birth cohort 1988-
1995 for (A) HPV 16 or 18 (B) HPV 31 or 33 or 45 (C) Other high risk HPV 
(not HPV 16/18/31/33/45) (D) Any HPV 
 
 
